In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Latest From MorphoSys AG

Keeping Track: Four Novel Agents Clear US FDA, Including Evrysdi, Blenrep

The latest US FDA approvals and actions from the Pink Sheet’s US FDA Performance Tracker.

US FDA Performance Tracker Approvals

Finance Watch: Notable Neuroscience VC Deals Include Nura Bio’s $73m Launch

Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.

Financing Neurology

Morphosys/Incyte’s Monjuvi Wins Early US FDA Approval In Second-Line DLBCL

Monjuvi’s good efficacy and safety profile should enable its broad adoption in the second line DLBCL space and help it compete well against rival CAR-T therapies, analysts said.

Approvals Cancer

Hanmi, Bioapp Accelerate Plant-Derived Coronavirus Vaccine

Hanmi is accelerating development of a plant-derived COVID-19 vaccine with Bioapp after successful early, the forming part of the leading South Korean pharma group’s post-pandemic business vision, which includes 'green biotech'.

South Korea Coronavirus COVID-19
See All

Company Information

  • Industry
  • Biotechnology
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Lanthio Pharma B.V.
    • MorphoSys US Inc.
    • Sloning BioTechnology
UsernamePublicRestriction

Register